Please ensure Javascript is enabled for purposes of website accessibility

Gilead Strikes Deal With Mylan to Supply Remdesivir Internationally

By Keith Speights – May 12, 2020 at 5:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mylan will distribute the drug as a COVID-19 treatment in 127 low- and middle-income countries.

Mylan (MYL) announced on Tuesday that it has entered into a global partnership with Gilead Sciences (GILD -1.43%) to manufacture and distribute remdesivir in 127 low- and middle-income countries as a treatment for COVID-19. Remdesivir showed promise against the novel coronavirus in late-stage clinical studies.

Why the deal happened

Because of the urgent nature of the pandemic, Gilead has indicated its desire to make remdesivir widely available as quickly as possible, and partnering with Mylan will help it accomplish that goal. The pharmaceutical companies have worked together for 15 years in their efforts to fight other infectious diseases including HIV and hepatitis C. Remdesivir is the 10th drug licensed by Gilead to Mylan.

Magnifying glass on top of blocks spelling out remdesivir

Image source: Getty Images.

Mylan brings to the table a global infrastructure and technical expertise in manufacturing injectable drugs that likely appealed to Gilead in this case. The drugmaker also has plenty of experience navigating the supply chain issues that can crop up when producing and delivering drugs to developing countries.

What's next

Mylan plans to develop a bioequivalent version of remdesivir and produce its own active pharmaceutical ingredient for the drug. The company expects to be able to provide remdesivir to India and other countries in the next few months, pending reviews by the regulatory agencies in those countries and a prequalification from the World Health Organization.

The agreement that will allow Mylan to produce the drug for low- and middle-income countries is non-exclusive, so Gilead can still sign up other licensees to manufacture and distribute remdesivir for use in treating COVID-19 patients across the world.

Keith Speights owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.86 (-1.43%) $0.91
Viatris Inc. Stock Quote
Viatris Inc.
MYL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.